Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death (Cleveland and Rothstein, 2001). Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease affecting the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language (Van Langenhove et al., 2012). Both ALS and FTLD are classified as proteinopathies in which abnormal protein aggregation and accumulation in neurons contribute to the disease pathogenesis. Fused in sarcoma (FUS) is a DNA/RNA-binding protein involved in various cellular processes, including transcriptional regulation, RNA splicing, and DNA repair. Mutations in the FUS gene have been linked to familial ALS, highlighting the importance of FUS in the disease pathogenesis (Vance et al., 2009). In ALS and FTLD, aberrant posttranslational modifications (PTMs) of FUS, such as phosphorylation, acetylation, and methylation, have been implicated in the promotion of FUS aggregation and neurotoxicity (Choi et al., 2023). Therefore, understanding the regulatory mechanisms of FUS PTMs is crucial for developing targeted therapies against these diseases.